Intellia Therapeutics: The Next Moderna? High Upside Potential in Gene Editing

Moderna, a biotech company, gained prominence during the pandemic with its mRNA-based COVID-19 vaccine. The stock soared over 1,200% between 2020 and 2022. Intellia Therapeutics, a gene-editing company, focuses on treatments for genetic diseases. It employs in vivo and ex vivo approaches and has promising therapies in late-stage trials. Intellia generated $16.6 million in collaboration revenue in Q1 and has enough cash to last until mid-2027. Analysts give Intellia a “Moderate Buy” rating with a price target implying 245% upside potential. Success in gene editing could lead to significant growth, similar to Moderna’s trajectory.

Read more at Yahoo Finance: The Next Moderna? This Clinical-Stage Biotech Has Breakout Potential.